Black Rock Inc. Icosavax, Inc. Transaction History

Black Rock Inc.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	BUY	$5.95 - $15.79 $3.48 Million - $9.24 Million	585,250 Added 29.32%	2,581,530 $40.7 Million
Q3 2023 Nov 13, 2023	BUY	$7.22 - $10.05 $1.52 Million - $2.11 Million	210,140 Added 11.77%	1,996,280 $15.5 Million
Q2 2023 Aug 11, 2023	BUY	$4.89 - $10.57 $2.33 Million - $5.03 Million	475,777 Added 36.31%	1,786,140 $17.7 Million
Q1 2023 May 12, 2023	SELL	$5.62 - $11.51 $319,940 - $655,252	-56,929 Reduced 4.16%	1,310,363 $7.6 Million
Q4 2022 Feb 13, 2023	SELL	$2.32 - $10.97 $337,689 - $1.6 Million	-145,556 Reduced 9.62%	1,367,292 $10.9 Million
Q3 2022 Nov 14, 2022	SELL	$3.09 - $9.21 $74,039 - $220,680	-23,961 Reduced 1.56%	1,512,848 $4.78 Million
Q2 2022 Aug 12, 2022	BUY	$5.7 - $10.33 $137,843 - $249,810	24,183 Added 1.6%	1,536,809 $8.81 Million
Q1 2022 May 12, 2022	SELL	$4.41 - $22.5 $448,726 - $2.29 Million	-101,752 Reduced 6.3%	1,512,626 $10.7 Million
Q4 2021 Feb 10, 2022	BUY	$21.07 - $34.98 $779,758 - $1.29 Million	37,008 Added 2.35%	1,614,378 $36.9 Million
Q3 2021 Nov 09, 2021	BUY	$24.85 - $40.25 $39.2 Million - $63.5 Million	1,577,370 New	1,577,370 $46.7 Million

1.37M

Ticker ICVX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,885,200
Description
Icosavax, Inc., a biopharmaceutical company, develops vaccines against infectious diseases. The company, with the help of its virus-like particle (VLP) platform technology, focuses primarily on life-threatening respiratory diseases. Its products in pipeline include IVX-121, a vaccine candidate with RSV target and is under Phase 1/1b clinical tri...

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

Stay updated on Black Rock Inc. with notifications on news.